Celine Halioua is a brilliant biotech entrepreneur on a mission to extend the health and lifespan of dogs. She is the founder and CEO of Loyal, a startup that develops drugs to treat aging-related diseases and improve their quality of life. She is also a venture partner at The Longevity Fund, a VC firm that invests in companies aiming to increase human longevity.

Halioua has been fascinated by neuroscience and nanobiotechnology since her early years and worked in various research labs on topics such as gene therapy, regenerative medicine, and neuronal tracers. She graduated from the University of Texas at Austin with a degree in neuroscience and nanobiotechnology and then pursued a D.Phil. in health economics of gene therapy at Oxford University.

An avid animal lover who owns two dogs named Luna and Milo, Halioua founded Loyal, which is based in San Francisco. The company uses cutting-edge science and technology to discover and develop novel therapeutics that can delay or reverse the aging process in dogs. Loyal’s first drug, which targets a cellular mechanism that may prevent mental and physical decline associated with age, is expected to enter clinical trials in 2023. Loyal’s vision is to create a world where dogs can live longer, healthier, and happier lives with their human families.